Clinical trial
Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan…
NCT00414089 · AHS Cancer Control Alberta, Other · Withdrawn
Key facts
| NCT number | NCT00414089 |
|---|---|
| Title | Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL |
| Official title | Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | 90Y-ibritumomab tiuxetan (Zevalin) |
| Enrollment | 0 |
| First posted | Dec 21, 2006 |
| Last update posted | Feb 15, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: